VERAXA Biotech AG (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to advance the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership underscores a growing trend in the biopharmaceutical industry to integrate artificial intelligence into drug discovery and development processes.
The initial focus of the collaboration will be on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform. This platform is designed to improve tumor targeting while reducing off-target toxicity, a common challenge in cancer immunotherapy. By analyzing large preclinical and clinical datasets, the AI tools aim to enhance target selection, potentially reviving programs that showed efficacy but failed due to toxicity issues.
“Integrating artificial intelligence into our research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity,” a VERAXA representative stated. The company believes that this collaboration will strengthen the development of precision oncology therapies and improve long-term drug development success rates.
The partnership comes at a time when AI is increasingly being adopted in the pharmaceutical sector to streamline R&D, reduce costs, and increase the probability of clinical success. For VERAXA, which was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), leveraging AI could accelerate the progression of its pipeline into clinical development.
VERAXA’s BiTAC(R) technology represents a novel approach in the bispecific antibody space, and the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats. The collaboration with Ardigen is expected to provide a competitive edge by enabling data-driven decision-making in early-stage research.
For more details on the announcement, visit the full press release here. Additional information about VERAXA Biotech AG is available in the company’s newsroom at http://ibn.fm/VRXA.
